Sofosbuvir 400 mg + Velpatasvir 100 mg
This pan-genotypic direct-acting antiviral combination targets key steps in the hepatitis C virus (HCV) replication cycle, enabling effective management of chronic HCV infection under internationally recognized treatment protocols.
Product Details
Therapeutic Class
Direct-Acting Antivirals (DAAs)
NS5B Polymerase Inhibitor (Sofosbuvir)
NS5A Inhibitor (Velpatasvir)
Indication
Treatment of chronic hepatitis C virus (HCV) infection in adults, in accordance with WHO-recommended treatment guidelines.
Dosage & Administration
One tablet once daily, or as prescribed by a healthcare professional.
To be used strictly as part of a guideline-recommended HCV treatment regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
30 Tablets
Sofosbuvir 400 mg + Velpatasvir 100 mg
This pan-genotypic direct-acting antiviral combination targets key steps in the hepatitis C virus (HCV) replication cycle, enabling effective management of chronic HCV infection under internationally recognized treatment protocols.
Product Details
Therapeutic Class
Direct-Acting Antivirals (DAAs)
NS5B Polymerase Inhibitor (Sofosbuvir)
NS5A Inhibitor (Velpatasvir)
Indication
Treatment of chronic hepatitis C virus (HCV) infection in adults, in accordance with WHO-recommended treatment guidelines.
Dosage & Administration
One tablet once daily, or as prescribed by a healthcare professional.
To be used strictly as part of a guideline-recommended HCV treatment regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
30 Tablets
Sofosbuvir 400 mg + Velpatasvir 100 mg
This pan-genotypic direct-acting antiviral combination targets key steps in the hepatitis C virus (HCV) replication cycle, enabling effective management of chronic HCV infection under internationally recognized treatment protocols.
Product Details
Therapeutic Class
Direct-Acting Antivirals (DAAs)
NS5B Polymerase Inhibitor (Sofosbuvir)
NS5A Inhibitor (Velpatasvir)
Indication
Treatment of chronic hepatitis C virus (HCV) infection in adults, in accordance with WHO-recommended treatment guidelines.
Dosage & Administration
One tablet once daily, or as prescribed by a healthcare professional.
To be used strictly as part of a guideline-recommended HCV treatment regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
30 Tablets